-
The Urologic Clinics of North America May 2014This article presents an overview of the challenges that men encounter in making decisions about prostate cancer screening, including complex affective and cognitive... (Review)
Review
This article presents an overview of the challenges that men encounter in making decisions about prostate cancer screening, including complex affective and cognitive factors and controversies in the interpretation of the evidence on prostate cancer screening. Shared decision making involving patient decision aids are discussed as approaches that can be used to improve the quality of prostate cancer screening decisions, including a close alignment between a man's values, goals, and preferences and his choice about screening.
Topics: Decision Making; Early Detection of Cancer; Humans; Male; Mass Screening; Practice Guidelines as Topic; Prostatic Neoplasms
PubMed: 24725488
DOI: 10.1016/j.ucl.2014.01.008 -
Future Oncology (London, England) 2015Despite radical treatment, many men with prostate cancer will develop recurrence of their disease. In an exciting era of new therapies for prostate cancer in general, we... (Review)
Review
Despite radical treatment, many men with prostate cancer will develop recurrence of their disease. In an exciting era of new therapies for prostate cancer in general, we focus on how these will specifically benefit those men with recurrent disease. We consider salvage treatments aimed at those with local recurrence confined to the prostate gland, therapies for those presenting with metastatic recurrence and the approach to men presenting with a rising prostate-specific antigen but no demonstrable disease (M0). In general, men with recurrent disease are often under-represented in randomized clinical trials. Consequently, evidence to guide treatment for these men is often lacking and this needs to be addressed in order to improve and better define our approach to this problem in the future.
Topics: Chemotherapy, Adjuvant; Disease Management; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retreatment; Salvage Therapy
PubMed: 26436556
DOI: 10.2217/fon.15.228 -
Discovery Medicine Feb 2012Prostate cancer is the most common malignant neoplasm in men and the second most frequent cause of cancer death for males in the United States. Recently, emerging... (Review)
Review
Prostate cancer is the most common malignant neoplasm in men and the second most frequent cause of cancer death for males in the United States. Recently, emerging evidence suggests that prostate cancer stem cells (CSCs) may play a critical role in the development and progression of prostate cancer. Therefore, targeting prostate CSCs for the prevention of tumor progression and treatment of prostate cancer could become a novel strategy for better treatment of patients diagnosed with prostate cancer. In this review article, we will summarize the most recent advances in the prostate CSCs field, with particular emphasis on targeting prostate CSCs to treat prostate cancer.
Topics: Animals; Humans; Male; Mice; Neoplastic Stem Cells; Prostatic Neoplasms
PubMed: 22369972
DOI: No ID Found -
Clinica Chimica Acta; International... Dec 2015In the United States of America male prostate cancer (PCa) is the most dominant malignancy and the second highest cause of cancer-related mortality risk compared to lung... (Review)
Review
In the United States of America male prostate cancer (PCa) is the most dominant malignancy and the second highest cause of cancer-related mortality risk compared to lung and colon cancers. MicroRNAs (miRNAs) are a class of endogenously expressed small, non-coding, single-stranded RNA which function as regulators of gene expression. They influence various physiological and pathophysiological processes. In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed.
Topics: Cell Cycle; Cell Proliferation; Humans; Male; MicroRNAs; Prostatic Neoplasms; Receptors, Androgen
PubMed: 26415820
DOI: 10.1016/j.cca.2015.09.022 -
Magyar Onkologia Mar 2019As a result of the growing incidence of cancer as well as increased survival of patients, an increasing number of people are living longer with cancer. In recent years,... (Review)
Review
As a result of the growing incidence of cancer as well as increased survival of patients, an increasing number of people are living longer with cancer. In recent years, research has shown that physical activity not only protects against a number of cancer types, but is also valuable for patients undergoing cancer treatment and during the rehabilitation phase, as well as for improving function and quality of life. Regular physical activity is an effective way to reduce the side effects of cancer, resulting in part from physical inactivity and in part from the disease itself. Too much rest can lead to a decrease in aerobic fitness, strength, mobility and unwanted weight gain in the patient. In prostate cancer patients, hormonal treatment especially accelerates this process. In this paper we summarize the available evidence concerning the role of exercise in prostate cancer prevention, treatment and rehabilitation.
Topics: Exercise; Humans; Male; Prostatic Neoplasms; Quality of Life
PubMed: 30889622
DOI: No ID Found -
Current Opinion in Oncology May 2021Present highlights from recent research examining the treatment of advanced prostate cancer. (Review)
Review
PURPOSE OF REVIEW
Present highlights from recent research examining the treatment of advanced prostate cancer.
RECENT FINDINGS
Although debate remains about the optimal sequencing of docetaxel and novel androgen directed therapies in addition to androgen deprivation therapy (ADT) in the treatment of men with new metastatic prostate cancer, the novel LHRH antagonist relugolix seems poised to become an appealing option in a choice of initial ADT. Novel radioisotopes, genomically selected therapies, and immune therapy combinations show progress in opening up new treatment options for men with castration-resistant prostate cancer.
SUMMARY
Although no clear consensus has emerged, evolving data continue to refine the selection of systemic therapies in treatment naïve metastatic prostate cancer. With potentially less cardiotoxic androgen deprivation therapies, novel radioisotopes, targeted pharmaceuticals, and immune therapy combinations, progress appears to be on the horizon in improving outcomes for men with advanced prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Male; Neoplasm Metastasis; Phenylurea Compounds; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyrimidinones; Radiopharmaceuticals; Randomized Controlled Trials as Topic
PubMed: 33818543
DOI: 10.1097/CCO.0000000000000723 -
World Journal of Urology Dec 2010
Topics: Antigens, Neoplasm; Biomarkers, Tumor; Humans; Magnetic Resonance Imaging; Male; Prostatectomy; Prostatic Neoplasms
PubMed: 20976601
DOI: 10.1007/s00345-010-0607-6 -
The Journal of Urology Apr 1996
Topics: Cost-Benefit Analysis; Humans; Male; Neoplasm Staging; Prognosis; Prostatic Neoplasms
PubMed: 8632573
DOI: 10.1016/s0022-5347(01)66265-7 -
Prostate Cancer and Prostatic Diseases Sep 2022
Topics: Exercise; Humans; Male; Prostatic Neoplasms; Quality of Life
PubMed: 35181745
DOI: 10.1038/s41391-022-00509-6 -
Medecine Sciences : M/S 2017Prostate cancer is a public health concern as it currently represents the most frequent malignancy in men in Europe. Progression of this hormone-dependent cancer is... (Review)
Review
Prostate cancer is a public health concern as it currently represents the most frequent malignancy in men in Europe. Progression of this hormone-dependent cancer is driven by androgens. Thus, the most common treatment for patients with advanced prostate cancer consists in an androgen ablation by castration therapy. However, the majority of patients relapses and develops a castration-resistant prostate cancer. This failure of androgen deprivation is related to the emergence of mutant and splice variants of the androgen receptor. Indeed, androgen receptor variants are ligand-independent, constitutively active and thus able to induce resistance to castration. This review focuses on AR variants signaling pathways and their role in resistance to castration and prostate cancer progression.
Topics: Castration; Disease Progression; Drug Resistance, Neoplasm; Humans; Male; Polymorphism, Genetic; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction
PubMed: 28945566
DOI: 10.1051/medsci/20173308021